BioSpace News Archive

CytoSorbents Corporation announced that the Company will participate in the 10th EuroELSO Congress in London, UK being held May 4-6, 2022, one of the two major conferences for ECMO users worldwide.

BeiGene announced that the BTK inhibitor BRUKINSA has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström’s macroglobulinemia.

Seres Therapeutics, Inc. a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update.

Orthofix Medical Inc. announced that it plans to release financial results for the first quarter 2022 before market open on Friday, May 6, 2022.

Optum Rx, the pharmacy care services business of UnitedHealth Group, is donating 5,000 at-home COVID-19 rapid antigen self-tests to increase access to COVID-19 testing and support for underserved communities across Chicago.

April 28, 2022 11:00 UTC ULTOMIRIS ® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalized myasthenia gravis ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks WILMINGTON, Del.--( BUSINESS WIRE )-- ULTOMIRIS ® (rav

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure reported financial results for the quarter ended March 31, 2022.

Moderna, Inc. today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration.

Intellia Therapeutics, Inc. will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET.

InspireMD, Inc. announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens.